New article: “Recombinant Protein Drugs: A 2025 Update”

Abstract:

Over the past decade, recombinant protein therapeutics have moved from conventional biologics toward highly engineered, multifunctional versions. Enabled by innovations in synthetic biology, host cell engineering, and bioprocess optimization, proteins are increasingly viewed not only as drugs for replacement therapies but also as fully versatile platforms in innovative therapeutic approaches aiming at functional reprogramming. Advances in host systems, from optimized microbial strains to mammalian and plant-based platforms, have expanded the range of proteins that can be produced with high fidelity, scalability, and safety. In parallel, modular protein engineering has delivered next-generation formats, including bispecific anti-bodies, nanobodies, fusion proteins, and self-assembling biomaterials, broadening therapeutic applications across oncology, inflammation, metabolic disorders, and beyond. At the same time, regulatory frameworks are adapting to support accelerated approval of personalized and complex biologics, while decentralized and flexible manufacturing models begin to emerge. This review provides a 2025 update on the field of recombinant protein drugs, integrating advances in production platforms, pro-tein engineering, and regulatory science, and outlining how these technologies are shaping the next generation of biologics.

Article data:

Hèctor López-Laguna, Eloi Parladé, Marianna T. P. Favaro, Carlos Palacín, Eric Voltà-Durán, Neus Ferrer-Miralles, José Luis Corchero, Rosalía Rodríguez-Rodríguez, Esther Vázquez, Ugutz Unzueta, Antonio Villaverde. Recombinant Protein Drugs: A 2025 Update. Biodrugs(2026). https://doi.org/10.1007/s40259-026-00783-z

DOI:10.1007/s40259-026-00783-z